Referred to the House Committee on Ways and Means.
The bill creates a new federal tax credit (section 45BB) paying producers a per-gallon subsidy for domestically produced, tetra-ethyl-lead-free aviation gasoline sold in the United States. The per-gallon credit phases from $1.25 in 2026 to $1.05 in 2030 and sunsets after December 31, 2030.
Progressives emphasize public-health and environmental benefits
Relative to its intended legislative type, this bill is a clearly structured tax-policy measure that specifies credit amounts, eligibility, and administrative responsibilities, and it pairs the credit with a mandated GAO study.
The bill creates a new federal tax credit (section 45BB) paying producers a per-gallon subsidy for domestically produced, tetra-ethyl-lead-free aviation gasoline sold in the United States.
The per-gallon credit phases from $1.25 in 2026 to $1.05 in 2030 and sunsets after December 31, 2030.
Producers must register and certify fuel as qualified; Treasury must issue regulations after consulting DOT.
Technocratic, narrow incentive with sunset and study improves prospects, but tax expenditure and need for bipartisan coalition or package inclusion limit standalone chances.
Relative to its intended legislative type, this bill is a clearly structured tax-policy measure that specifies credit amounts, eligibility, and administrative responsibilities, and it pairs the credit with a mandated GAO study. It integrates cleanly into the Internal Revenue Code but omits fiscal impact discussion and some enforcement and reporting detail.
Progressives emphasize public-health and environmental benefits
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives emphasize public-health and environmental benefits
Likely generally supportive because the credit promotes removal of lead from aviation fuel and reduces community exposure.
Views the measure as a targeted, market-based tool to accelerate a public-health transition.
May worry the incentive is too small or too temporary to guarantee rapid phaseout without stronger regulatory backstops.
Cautiously favorable as a targeted, time-limited incentive to address a clear public-health externality.
Appreciates the GAO study and sunset, but wants clarity on budgetary cost-effectiveness and actual market impacts.
Will watch regulatory guidance and pass-through evidence before full endorsement.
Skeptical due to new federal subsidies and regulatory certification requirements.
Views the credit as a market distortion and potential fiscal cost without guaranteed consumer benefits.
May accept limited support if it demonstrably reduces regulatory mandates or fosters voluntary private solutions.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Technocratic, narrow incentive with sunset and study improves prospects, but tax expenditure and need for bipartisan coalition or package inclusion limit standalone chances.
The bill has not accumulated any surfaced votes yet.
Progressives emphasize public-health and environmental benefits
Technocratic, narrow incentive with sunset and study improves prospects, but tax expenditure and need for bipartisan coalition or package i…
Relative to its intended legislative type, this bill is a clearly structured tax-policy measure that specifies credit amounts, eligibility, and administrative responsibilities, and it pairs the credit with a mandated GA…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.